4-[8-{2-[4-(4-Phenylbutoxy)phenyl]ethyl}-2-(1H-tetraazol-5-yl)-2,3-dihydro-4H-1,4-benzoxazin-4-yl]butanoic acid

ID: ALA3403185

Chembl Id: CHEMBL3403185

PubChem CID: 11353238

Max Phase: Preclinical

Molecular Formula: C31H35N5O4

Molecular Weight: 541.65

Molecule Type: Small molecule

Names and Identifiers

Canonical SMILES:  O=C(O)CCCN1CC(c2nnn[nH]2)Oc2c(CCc3ccc(OCCCCc4ccccc4)cc3)cccc21

Standard InChI:  InChI=1S/C31H35N5O4/c37-29(38)13-7-20-36-22-28(31-32-34-35-33-31)40-30-25(11-6-12-27(30)36)17-14-24-15-18-26(19-16-24)39-21-5-4-10-23-8-2-1-3-9-23/h1-3,6,8-9,11-12,15-16,18-19,28H,4-5,7,10,13-14,17,20-22H2,(H,37,38)(H,32,33,34,35)

Standard InChI Key:  LVVXXWCIOYFPSY-UHFFFAOYSA-N

Alternative Forms

1. Parent:

   

   ALA3403185

   4-[8-[2-[4-(4-phenylbutoxy)phenyl]ethyl]-2-(2H-tetrazol-5-yl)-2,3-dihydro-1,4-benzoxazin-4-yl]butanoic acid

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Calculated Properties

Molecular Weight: 541.65

Molecular Weight (Monoisotopic): 541.2689

AlogP: 5.19

#Rotatable Bonds: 14

Polar Surface Area: 113.46

Molecular Species: ACID

HBA: 7

HBD: 2

#RO5 Violations: 2

HBA (Lipinski): 9

HBD (Lipinski): 2

#RO5 Violations (Lipinski): 2

CX Acidic pKa: 3.51

CX Basic pKa: 1.70

CX LogP: 6.30

CX LogD: 1.48

Aromatic Rings: 4

Heavy Atoms: 40

QED Weighted: 0.21

Np Likeness Score: -0.42

References

1. Itadani S, Takahashi S, Ima M, Sekiguchi T, Aratani Y, Egashira H, Matsumura N, Inoue A, Yonetomi Y, Fujita M, Nakayama Y, Takeuchi J..  (2015)  Discovery of a potent, orally available dual CysLT₁ and CysLT₂ antagonist with dicarboxylic acid.,  23  (9): [PMID:25800431] [10.1016/j.bmc.2015.03.011]

Source

Source(1):

• Scientific Literature